Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation

Internal and Emergency Medicine

Volumn 5, Issue 5, 2010, Pages 421-426

  Simonian, Sharis M ^a   Lotfipour, Shahram ^b   Wall, Christopher ^c   Langdorf, Mark I ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

Amiodarone; Atrial fibrillation; Procainamide; Wolff Parkinson White (WPW)

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; PROCAINAMIDE;

ADULT; CASE REPORT; ELECTROCARDIOGRAPHY; EMERGENCY HEALTH SERVICE; HEART ATRIUM FIBRILLATION; HUMAN; MALE; REVIEW; TACHYCARDIA; WOLFF PARKINSON WHITE SYNDROME;

ADULT; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ELECTROCARDIOGRAPHY; EMERGENCY SERVICE, HOSPITAL; HUMANS; MALE; PROCAINAMIDE; TACHYCARDIA; WOLFF-PARKINSON-WHITE SYNDROME;

EID: 77956872069     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-010-0385-6     Document Type: Review

References (16)

1. AHA (2005) American heart association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Part 7. 3: Management of symptomatic bradycardia and tachycardia. Circ 112: IV-67-IV-77.
2. Boriani G, Biffi M, Frabetti L et al (1996) Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation. Am Heart J 131: 1214-1216.
3. Cummins RO, Hazinski MF (2006) The quest for a terminator. Ann Emerg Med 47: 227-229.
4. Fengler BT, Brady WJ, Plautz CU (2007) Atrial fibrillation in the Wolff-Parkinson-White syndrome: ECG recognition and treatment in the ED. Am J Emerg Med 25: 576-583.
5. Kappenberger LJ, Fromer MA, Steinbrunn W et al (1984) Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation. Am J Cardiol 54: 330-335.
6. Li P (1991) Electrophysiological properties of atrial fibrillation with WPW syndrome and the role of procainamide in conversion. Chin J Cardiovasc Dis 19: 65-66 123.
7. Madrid AH, Moro C, Maŕin Huerta EM et al (1992) Atrial fibrillation in Wolff-Parkinson-White syndrome: reversal of isoproterenol effects by sotalol. Pacing Clin Electrophysiol 15: 2111-2115.
8. Marill KA, deSouza IS, Nishijima DK et al (2006) Amiodarone is poorly effective for the acute termination of ventricular tachycardia. Ann Emerg Med 47: 217-224.
9. Pastor A, Almendral JM, Ormaetxe J et al (1993) Ventricular fibrillation during treatment of atrial fibrillation with intravenous amiodarone in patients with the WPW syndrome [abstract]. Eur Heart J 14(Suppl): 294.
10. Prystowsky EN, Benson DW Jr, Fuster V et al (1996) Management of patients with atrial fibrillation. A statement for healthcare professionals. From the subcommittee on electrocardiography and electrophysiology. American Heart Association. Circulation 93: 1262-1277.
11. Prystowsky EN, Katz AM (1998) Atrial fibrillation. In: Textbook of cardiovascular medicine. Lippincott-Raven. Philadelphia, Pennsylvania, p 1661.
12. Schatz I, Ordog GJ, Karody R et al (1987) Wolff-Parkinson-White syndrome presenting in atrial fibrillation. Ann Emerg Med 16: 574-578.
13. Schützenberger W, Leisch F, Gmeiner R (1987) Enhanced accessory pathway conduction following intravenous amiodarone in atrial fibrillation. A case report. Int J Cardiol 16: 93-95.
14. Schützenberger W, Leisch F, Kerschner K et al (1989) Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation. Br Heart J 62: 367-371.
15. Sheinman BD, Evans T (1982) Acceleration of ventricular rate by fibrillation associated with the Wolff-Parkinson-White syndrome. Br Med J (Clin Res Ed. 1981) 285: 999-1000.
16. Tijunelis MA, Herbert ME (2005) Myth: intravenous amiodarone is safe in patients with atrial fibrillation and Wolff-Parkinson-White syndrome in the emergency department. J Canad Assoc Emerg Phys 7: 262-265.